New Employee Elected Directors to the Board of Zealand Pharma A/S

Udgivet den 13-03-2024  |  kl. 21:00  |  

Company announcement - No. 14 / 2024

New Employee Elected Directors to the Board of Zealand Pharma A/S

Copenhagen, Denmark, March 13, 2024 - Zealand Pharma A/S ("Zealand") (NASDAQ: ZEAL) (CVR-no. 20 04 50 78). The employees of Zealand Pharma A/S have elected the following employee representatives and alternates for the Company's Board of Directors:

Employee representatives:

Frederik Beck (re-elected)Anneline Nansen (re-elected)Ludovic Otterbein (newly elected) Adam Nygaard (newly elected)

As alternates for the employee-elected board members, the following were elected:

Tanja ErichsenKatja HansenLars PedersenCecilie Kold

The new employee-elected board members will join the Board of Directors following the annual general meeting of Zealand Pharma A/S on 20 March 2024. At the same time the current board members Jens Peter Stenvang, who did not run for election, and Louise Gjelstrup, who did not run for election, will step down from their positions on the Board.

About employee-elected board members

According to the Danish Companies Act, the employees of Zealand Pharma A/S are entitled to be represented by half of the total shareholder-elected Board members. Employee-elected board members serve for a statutory four-year term and have the same rights, duties and responsibilities as shareholder-elected board members.

# # #

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq: ZEAL) (Zealand) is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of blue-chip pharma companies as well as commercial partnerships for its marketed products.

Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the U.S. For more information about Zealand's business and activities, please visit www.zealandpharma.com.

Contact:

Anna Krassowska, PhD
Vice President, Investor Relations & Corporate Communications
Zealand Pharma
Email: ank@zealandpharma.com


\Hugin

Udgivet af: NPinvestordk

Seneste nyheder

14:01 USA/tendens: Marginale plusser inden forkortet handelsdag og masser af nøgletal
13:08 Valuta: Dollarsvækkelse fortsætter efter kommentarer fra Jerome Powell
12:27 Carlsberg efter fald på 10 pct.: En klar købsmulighed ifølge Jyske Bank
12:04 Europa/aktier: Tysk våbenkæmpe topper mens vindaktie sendes ned
11:54 Vestas-aktien presset af kinesiske møller på vej til Europa
11:46 Aktier/middag: C25 halter efter Europa - Novo og Vestas trækker ned
11:38 Trygs pressechef takker af efter næsten et årti
11:32 Obligationer/middag: Let stigende rente før storm af nøgletal i USA
11:10 Vilde udsving for tysk it-firma efter planer om børsnotering af AI og Cloud-forretning
11:04 Korr: Medie: It-udfordringer bag Mærsks droppede bud på DB Schenker
10:45 Medie: It-udfordringer bag Mærsks droppede bud på DB Schenker
09:14 Aktier/åbning: C25 går mod strømmen i Europa - Vestas og Novo tynger
09:07 Novo bombarderer amerikanske tv-seere med reklamer for Wegovy
08:59 Obligationer/åbning: Stilhed før nøgletalsstormen
08:49 Forsikrings- og pensionssektor fik positivt afkast i maj viser tal fra Nationalbanken
08:30 Aktier/tendens: Udsigt til grøn start på stille dag - Novo giver igen efter Biden-kritik
07:27 Novo om Bidens kritik af priser: Et komplekst problem misbruges til politiske formål
07:18 Råvarer: Oliepriserne stiger på fald i amerikanske olielagre
07:01 Obligationer/tendens: Sværm af nøgletal med enkelte afbrydelser fra ECB og Fed
06:41 Asien: Amerikanske kommentarer sender positive signaler gennem markedet